Skip to main content
main-content

Video+

VideoBytes

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

25-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Improving immune response against influenza in patients with RA

Inés Colmegna talks to us about her study showing the impact of a high-dose influenza vaccine on the immune response of patients with rheumatoid arthritis (11:17).

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

24-10-2018 | Pediatric | ACR/ARHP 2018 | Video

Expert highlights: Sangeeta Sule

Editorial board member Sangeeta Sule discusses her highlights from the pediatric rheumatology sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA (2:14).

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Expert commentary: Influzena vaccination in RA patients

Infectious disease specialist Kevin Winthrop comments on the study by Inés Colmegna and colleagues looking at the effects of a high-dose influenza vaccine on immune response in patients with rheumatoid arthritis (6:27).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

22-10-2018 | Giant cell arteritis | ACR/ARHP 2018 | Video

Axillary artery ultrasound proposed as first-line imaging test for large vessel giant cell arteritis

Berit Dalsgaard Nielsen discusses Aarhus University study findings showing the potential for ultrasound as a first-line imaging test for diagnosing large vessel inflammation in patients with suspected giant cell arteritis (4:57).

26-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Trial results on upadacitinib for the treatment of RA

Roy Fleischmann comments on the results of the SELECT-MONOTHERAPY and SELECT-NEXT trials, which provide further evidence for the benefits of upadacitinib in patients with RA (6:18).

Read the accompanying news story

19-06-2018 | Psoriatic arthritis | EULAR 2018 | Video

Expert commentary: Low rates of radiographic progression with secukinumab treatment in PsA patients

Douglas Veale comments on study results showing that secukinumab-treated PsA patients have low rates of radiographic progression regardless of prior TNF inhibitor exposure or concomitant methotrexate treatment (2:45).

Read the accompanying news story

18-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: Malignancy and infection risk with JAK inhibitors in RA patients

EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors (5:44).

Read the accompanying news story

15-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Researcher comment: MRI monitoring may not be justified in RA patients in clinical remission

Signe Møller-Bisgaard discusses her findings from the IMAGINE-RA study looking at the effects of adding the target of no osteitis or bone marrow edema on MRI to a conventional treat-to-target regimen in patients with RA (5:10).

Read the accompanying news story

15-06-2018 | Systemic lupus erythematosus | EULAR 2018 | Video

Expert commentary: Promising results with herpes zoster vaccine in SLE patients

Thomas Dörner comments on study results demonstrating that a live attenuated herpes zoster vaccine is well tolerated and provokes an antibody response in patients with SLE (5:14).

Read the accompanying news story here

14-06-2018 | TNF inhibitors | EULAR 2018 | Video

Researcher comment: Role of TNF inhibitors on need for joint replacement in RA

​​​​​​​Samuel Hawley comments on his research findings showing that TNF inhibitors might not play as big a role in the recent reduction in joint replacement procedures in patients with RA as originally thought and that additional factors are likely to be involved. (2:59)

Read the related news story

14-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

Expert commentary: COBRA trial 23-year follow-up analysis on mortality rates

Elena Nikiphorou provides her thoughts on the findings of this trial showing a normalization of mortality in patients with rheumatoid arthritis receiving early, intensive treatment (2:41).

Read the accompanying news story here.

03-05-2018 | Conferences | Video

Managing JIA-associated uveitis: The SHARE recommendations

In this video, Athimalaipet Ramanan gives an overview of the key points from the SHARE initiative consensus recommendations on the screening, diagnosis, and management of juvenile idiopathic arthritis-associated uveitis.

09-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: Tapping into technology to manage juvenile idiopathic arthritis

Editorial Board member Sangeeta Sule discusses a trial of an online self-management tool for adolescents with juvenile idiopathic arthritis, and the role of technology and education to manage the condition.

09-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: Biologic use during pregnancy and infection risk in infants

Bonnie Bermas provides an independent viewpoint on the results of a study suggesting that the use of biologic agents by women with rheumatoid arthritis during pregnancy is not associated with an increased serious infection risk for their babies.

08-11-2017 | Axial spondyloarthritis | ACR/ARHP 2017 | Video

Expert commentary: The ABILITY-3 trial

Walter Maksymowych comments on the ABILITY-3 trial results showing that continued adalimumab treatment is important for the maintenance of remission among patients with nonradiographic axial spondyloarthritis.

Read the accompanying news story

08-11-2017 | Osteoporosis | ACR/ARHP 2017 | Video

Expert commentary: Bisphosphonate drug holidays and fracture risk

Linda Russell gives an independent comment on a study showing that suspending bisphosphonate treatment for more than 2 years is associated with increased fracture risk.

Read the accompanying news story

image credits